Drug intelligence / Profile preview

V505

Development stage: Phase 2
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Injection

Overview

V505 is a multivalent Human Papilloma Virus (HPV) L1 Virus Like Particle (VLP) vaccine developed by Merck Sharp & Dohme LLC. It is being investigated in clinical trials to evaluate its tolerability and immunogenicity in healthy 16 to 26-year-old women, with comparisons made to GARDASIL.

Other names: Multivalent Human Papillomavirus L1 Virus Like Particle VaccineMultivalent HPV L1 VLP Vaccine

Targets

HPV L1 (Human papillomavirus L1 capsid protein)

Beyond the preview

Go deeper on V505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V505.

Explore the full profile